PT-141, known by its clinical name bremelanotide, is the only FDA-approved medication for sexual dysfunction that works through the brain rather than the body. Every other approved treatment for sexual dysfunction — from PDE5 inhibitors in men to topical estrogen in women — acts on peripheral tissue. PT-141 is fundamentally different. It activates melanocortin receptors in the central nervous system to generate sexual desire and arousal at the neurological level, which is why it works in situations where conventional treatments do not.
This article explains what PT-141 is, how its mechanism differs from every other sexual health treatment, what the clinical evidence shows, who it is appropriate for, and what the realistic expectations are for treatment. For context on how hormonal imbalances contribute to sexual dysfunction alongside and independently of desire, see our articles on erectile dysfunction and hormones, low testosterone in women, and our sexual health service page.
Quick answer
PT-141 (bremelanotide) is an FDA-approved subcutaneous injection used to treat hypoactive sexual desire disorder (HSDD) in premenopausal women, and is used off-label for sexual dysfunction in men. It works by activating melanocortin receptors in the brain to increase sexual desire and arousal through a central nervous system mechanism. Unlike Viagra or Cialis, it does not depend on physical stimulation or vascular response. It is administered as a self-injection approximately 45 minutes before anticipated sexual activity.
What Is PT-141 and Where Does It Come From?
PT-141 was originally developed as a tanning agent. Researchers noticed during early clinical trials that participants reported spontaneous sexual arousal as an unexpected side effect of the compound. This observation redirected decades of research toward sexual medicine, ultimately resulting in FDA approval under the brand name Vyleesi in June 2019.
Bremelanotide is a cyclic heptapeptide analog of alpha-melanocyte stimulating hormone (alpha-MSH), a naturally occurring neuropeptide that activates melanocortin receptors throughout the brain and body. By mimicking this natural peptide with greater potency and duration of action, PT-141 produces meaningful activation of the melanocortin pathways that regulate sexual motivation, arousal, and behavior at the central nervous system level.
Background: melanocortin receptors
The melanocortin system includes five receptor subtypes (MC1R through MC5R) distributed throughout the brain and peripheral tissues. MC3R and MC4R are concentrated in the hypothalamus and limbic system, brain regions that regulate sexual motivation and reward. PT-141 activates these receptors specifically in areas associated with sexual behavior, which is why its effects are centrally mediated rather than purely vascular. The same system also regulates appetite, mood, and stress responses, which explains some of the broader physiological effects observed with melanocortin activation.
How PT-141 Works: Central vs Peripheral Mechanism
Understanding why PT-141 is genuinely different from every other approved sexual health treatment requires understanding the two different levels at which sexual dysfunction can occur and be treated.
PDE5 inhibitors such as sildenafil (Viagra) and tadalafil (Cialis) work by relaxing smooth muscle in the blood vessels of the genitals, increasing blood flow in response to physical or psychological sexual stimulation that is already occurring. They amplify the vascular component of arousal. They do not generate desire. They require pre-existing arousal to work. If desire is absent — as it is in hypoactive sexual desire disorder — a PDE5 inhibitor provides no benefit.
Central treatment (PT-141)
PT-141 acts on the brain before any arousal has occurred. By activating MC3R and MC4R receptors in the hypothalamus, it initiates the neurological cascade that generates sexual desire and arousal from the top down. The result is spontaneous sexual interest that does not depend on prior stimulation. This makes PT-141 uniquely useful for patients whose primary complaint is absent or severely reduced desire rather than the physical mechanics of arousal and erectile or lubrication function.
PT-141 vs PDE5 Inhibitors: Key Differences
Feature
PT-141 (bremelanotide)
PDE5 inhibitors (Viagra/Cialis)
Mechanism
Central — activates brain melanocortin receptors to generate desire
Peripheral — increases genital blood flow in response to existing stimulation
Requires prior arousal?
No — generates desire independently
Yes — requires sexual stimulation to work
FDA approval
Yes — HSDD in premenopausal women (Vyleesi, 2019)
Yes — erectile dysfunction in men
Addresses low desire?
Yes — primary indication
No — addresses mechanics, not desire
Delivery
Subcutaneous injection (self-administered, abdomen or thigh)
Oral tablet
Timing
45 minutes before anticipated sexual activity
30–60 minutes before (sildenafil) or daily dosing (tadalafil)
Cardiovascular contraindication
Yes — avoid in patients with high cardiovascular risk
Yes — especially with nitrate medications
PT-141 for Women: FDA Approval and HSDD
Hypoactive sexual desire disorder (HSDD) is the most common female sexual dysfunction, estimated to affect 10 to 15% of premenopausal women when defined by both low desire and personal distress about that low desire. It is characterized by persistently or recurrently absent or deficient sexual desire that causes significant personal distress and is not explained by a medical condition, relationship difficulty, or medication effect alone.
PT-141 (Vyleesi) received FDA approval in June 2019 for HSDD in premenopausal women. It was the second approved pharmacological treatment for this condition, following flibanserin (Addyi, 2015). Vyleesi is the first injectable option and the first on-demand treatment. Unlike flibanserin, which requires daily dosing, bremelanotide is used only when sexual activity is anticipated.
The RECONNECT Trials: Clinical Evidence
In the two pivotal Phase 3 clinical trials (RECONNECT trials), bremelanotide produced statistically significant improvements in sexual desire scores and reductions in distress related to low sexual desire compared to placebo. Approximately 25% of women receiving bremelanotide reported a meaningful improvement in desire compared to approximately 17% in the placebo group, reflecting a modest but genuine treatment effect on a condition that had few pharmacological options previously.
The hormonal dimension of HSDD in women is important context. Low testosterone, estrogen deficiency, and thyroid dysfunction each independently contribute to reduced sexual desire. PT-141 addresses the neurological component of desire independent of hormonal status, which is why it can be effective even in women whose hormone levels are within normal range, and why it is sometimes most effective when used alongside hormonal optimization for women in whom both components are contributing. For women experiencing low desire alongside other hormonal symptoms, our article on low testosterone in women covers the hormonal side of the evaluation.
PT-141 for Men: Off-Label Use and Evidence
PT-141 is not FDA-approved for men, but its off-label use in male sexual dysfunction has been studied and is practiced within specialist settings. The original research that first identified PT-141’s sexual effects was conducted in men, and the compound’s mechanism is not sex-specific. Melanocortin receptors in the hypothalamus and limbic system regulate sexual motivation in both sexes through the same pathway.
What Early Clinical Trials in Men Showed
Early clinical trials showed PT-141 produced erections in men in a dose-dependent manner. Crucially, this included men who had not responded to sildenafil. PT-141 works centrally rather than peripherally, so it reaches men whose ED has a psychological or desire-related component rather than a purely vascular one. Men with normal testosterone but low sexual motivation — presenting as difficulty initiating activity rather than mechanical erectile failure — frequently benefit from PT-141 where PDE5 inhibitors alone fell short.
The distinction between desire-related and vascular ED is clinically important. It is not always made in primary care settings. For context on how hormones and vascular function interact, see our article on erectile dysfunction and hormones. Before starting PT-141, men should complete a full hormonal evaluation covering total and free testosterone, prolactin, thyroid, and estradiol. Low testosterone is the most common hormonal cause of reduced desire in men — and treating it may eliminate the need for PT-141 entirely. For the evaluation process, see our article on what to expect at a hormone therapy consultation.
Clinical note: combination protocols
PT-141 and PDE5 inhibitors work through entirely different mechanisms and can be used together. A man with both reduced desire (central component) and reduced erectile reliability (vascular component) may benefit from PT-141 addressing the motivational deficit alongside a PDE5 inhibitor addressing the vascular component. This combination approach requires medical supervision and careful dose management but is used in specialist practice. Similarly, PT-141 combined with testosterone optimization in hypogonadal men addresses both the hormonal and neurological dimensions of the sexual dysfunction picture simultaneously.
Dosing, Administration, and What to Expect
PT-141 is administered as a subcutaneous injection, typically into the abdomen or thigh. The FDA-approved dose for women is 1.75 mg injected approximately 45 minutes before anticipated sexual activity. Off-label use in men typically uses the same or similar doses with individual titration based on response and tolerability.
The onset of effect typically begins within 30 to 60 minutes and the duration of effect lasts approximately 12 to 24 hours for the desire-enhancing component. Unlike PDE5 inhibitors which primarily produce erectile effects lasting 4 to 6 hours, PT-141’s central effects on desire and arousal extend across a longer window, which many patients report as more natural feeling in terms of sexual spontaneity.
PT-141 Protocol: Key Parameters
Dose
1.75 mg subcutaneous (FDA-approved for women). Off-label doses in men typically 1 to 2 mg, titrated based on response and tolerability.
Timing
Inject 45 minutes before anticipated sexual activity. Effects begin within 30 to 60 minutes. Do not use more than once in 24 hours.
Frequency limit
FDA label limits use to a maximum of once per 24 hours and no more than 8 doses per month. Exceeding this increases risk of hyperpigmentation with chronic use.
Injection site
Abdomen or thigh, subcutaneous (just under the skin). Rotate injection sites with each use to minimize local reactions and hyperpigmentation risk.
Duration of effect
Desire-enhancing effects last 12 to 24 hours. Nausea side effect (if it occurs) typically peaks at 1 to 3 hours post-injection and resolves within 12 hours.
Storage
Refrigerate at 36 to 46°F (2 to 8°C). Can be stored at room temperature (up to 77°F) for up to 30 days. Do not freeze. Keep away from light.
Side Effects and Safety Considerations
PT-141 has a manageable side effect profile when used correctly. Two specific considerations require attention before starting treatment.
Nausea: The Most Common Side Effect
Approximately 40% of patients in clinical trials report nausea. It is the primary reason for discontinuation. Symptoms typically begin 30 to 60 minutes after injection, peak at 1 to 3 hours, and resolve within 12 hours without intervention. Injecting in the evening and sleeping shortly after reduces the impact significantly. For patients who find nausea limiting, providers can prescribe ondansetron (Zofran) as a prophylactic measure.
Hyperpigmentation: A Concern with Frequent Use
Bremelanotide activates MC1R receptors, which regulate skin pigmentation. Chronic use can cause focal hyperpigmentation at injection sites and occasionally on the face, gums, or breasts. The FDA limits use to 8 doses per month partly to address this. Patients with darker skin tones may be more susceptible. Hyperpigmentation typically fades after stopping the medication, though it can persist for months.
Blood Pressure Effects
PT-141 can transiently raise blood pressure by 2 to 4 mmHg in the first 12 hours post-injection. This effect is mild in patients with a normal cardiovascular baseline. However, PT-141 is contraindicated in patients with cardiovascular disease, uncontrolled hypertension, or high cardiovascular event risk. Baseline blood pressure should always be measured before starting treatment.
Contraindications: who should not use PT-141
PT-141 is contraindicated in patients with high cardiovascular risk including uncontrolled hypertension, known cardiovascular disease, history of stroke, or heart failure. It should not be used with medications that lower blood pressure. Women who are pregnant or breastfeeding should not use bremelanotide. Patients using nitrate medications for cardiovascular conditions face additional risk. A complete cardiovascular history and baseline blood pressure measurement are mandatory before initiating treatment.
PT-141 vs Flibanserin (Addyi): Choosing Between the Two FDA-Approved Options
For women with HSDD, two FDA-approved pharmacological options exist: flibanserin (Addyi) and bremelanotide (Vyleesi). They work through different mechanisms and suit different patient profiles.
Flibanserin is a daily oral tablet that acts on serotonin and dopamine receptors. It requires consistent daily dosing, carries significant drug interaction risks (particularly with alcohol and CYP3A4 inhibitors), and takes 4 to 8 weeks before meaningful benefit appears. Bremelanotide, by contrast, is taken on demand. It takes effect within 45 minutes and carries no alcohol interaction risk. Women who want situational rather than daily treatment will generally find PT-141 more practical. Women who prefer oral medication and are comfortable with daily use may prefer flibanserin despite its more complex management profile.
Tip: PT-141 and hormonal optimization work differently
PT-141 does not correct the hormonal causes of low libido. If low testosterone, thyroid deficiency, or elevated prolactin are driving reduced desire, PT-141 may provide situational symptom relief without addressing the underlying hormonal root cause. The most comprehensive approach combines hormonal evaluation and optimization with PT-141 where both a hormonal and a neurological component are contributing. For the full hormonal picture of sexual desire in women, see our article on low testosterone in women. For men, see our article on low testosterone effects and the sexual health service page.
Frequently Asked Questions
Is PT-141 FDA-approved?
Yes, for one specific indication. Bremelanotide (Vyleesi) received FDA approval in June 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Its use in men and in postmenopausal women is off-label. Off-label prescribing by licensed physicians is legal and common in medicine when clinical evidence supports the use, but it means these applications were not part of the formal FDA approval process.
How quickly does PT-141 work?
PT-141 typically begins to produce noticeable effects within 30 to 60 minutes of injection. The peak of effect for most patients occurs around 1 to 2 hours post-injection. The desire-enhancing effects typically last 12 to 24 hours, giving a relatively wide window of activity compared to oral PDE5 inhibitors. The recommended administration timing is 45 minutes before anticipated sexual activity.
Can PT-141 be used with Viagra or Cialis?
Yes, in appropriate patients and under medical supervision. PT-141 and PDE5 inhibitors work through entirely different mechanisms, so combining them addresses both the motivational (central) and vascular (peripheral) components of sexual dysfunction simultaneously. This combination is used in specialist practice for men who have both reduced desire and erectile difficulties. Blood pressure should be monitored as both agents can affect cardiovascular parameters, particularly with combination use.
Will PT-141 cause weight loss or affect my appetite?
Melanocortin receptors, which PT-141 activates, are also involved in appetite and energy regulation. In early research, melanocortin agonists were studied as appetite suppressants, and some patients do notice mild appetite reduction after PT-141 injection. However, bremelanotide at the approved dose is not prescribed or indicated for weight loss, and any appetite effect at standard doses is modest and transient. If weight management is a concern alongside sexual dysfunction, see our weight loss program for a dedicated evidence-based approach.
Does PT-141 work if my hormones are normal?
Yes. PT-141’s mechanism of action does not depend on hormone levels. It activates melanocortin receptors in the brain regardless of whether testosterone, estrogen, or other hormones are in the normal range. The FDA approval for HSDD in premenopausal women specifically addressed a population where hormone levels are generally normal. For patients with sexual desire difficulties and normal hormone labs, PT-141 addresses the neurological component that hormonal interventions cannot.
What is the difference between PT-141 and testosterone for low libido?
Testosterone addresses the hormonal root cause of low libido by restoring androgen levels that regulate the baseline hormonal drive for sexual interest. PT-141 generates an acute neurological response that increases desire regardless of hormone status. Testosterone takes weeks to months to show its full effect on libido and produces sustained improvement. PT-141 produces rapid effect that lasts 12 to 24 hours. For patients with confirmed low testosterone, TRT is typically the first-line approach. PT-141 may then be used for situational enhancement or if the desire response to TRT is incomplete.
Can PT-141 be used by postmenopausal women?
PT-141 is FDA-approved only for premenopausal women. Its use in postmenopausal women is off-label. The mechanism of action is not specific to menopause status — melanocortin receptors are present regardless of menopausal state — and some providers use it off-label in postmenopausal women with HSDD. However, postmenopausal women with sexual desire difficulties often have a significant estrogen and testosterone deficiency component that should be evaluated and addressed alongside any use of PT-141. For postmenopausal hormone considerations see our article on perimenopause and hormone therapy.
How do I manage nausea from PT-141?
Several strategies reduce the impact of PT-141-related nausea. Injecting in the evening allows nausea to run its course during sleep. Starting with a lower dose (0.75 to 1 mg) before titrating to the full 1.75 mg allows tolerance to build gradually. Avoiding a large meal in the 2 hours before injection reduces nausea severity. If nausea is significant, your provider can prescribe ondansetron (Zofran) to be taken prophylactically before injection. Most patients who persist through the first 2 to 3 uses find that nausea diminishes considerably with repeated exposure.
Interested in PT-141 or a complete sexual health evaluation?
Our specialists evaluate both the hormonal and neurological components of sexual dysfunction and design a treatment approach tailored to your specific picture. We work with both PT-141 and comprehensive hormonal optimization protocols.
This article is for informational and educational purposes only. It does not constitute medical advice, a diagnosis, or a treatment recommendation. PT-141 (bremelanotide / Vyleesi) is an FDA-approved prescription medication for HSDD in premenopausal women. Its use in other populations is off-label and requires individual clinical evaluation by a licensed provider. PT-141 carries cardiovascular contraindications and should only be used under medical supervision with a complete baseline evaluation including cardiovascular history and blood pressure measurement. If you are experiencing symptoms associated with sexual dysfunction or hormonal imbalance, consult a licensed provider for appropriate evaluation and testing.
